Literature DB >> 31898049

Comparison of Four Risk Prediction Models for Diabetes Remission after Roux-en-Y Gastric Bypass Surgery in Obese Chinese Patients with Type 2 Diabetes Mellitus.

HoiMan Kam1, Yinfang Tu1, Jiemin Pan1, Junfeng Han1, Pin Zhang2, Yuqian Bao3, Haoyong Yu4.   

Abstract

BACKGROUND: Roux-en-Y gastric bypass (RYGB) is a major type of bariatric surgery. Various models have been established for facilitating clinical decision-making and predicting outcomes after RYGB; the ABCD, DiaRem, advanced-DiaRem (Ad-DiaRem), and DiaBetter scores are among the most commonly used risk prediction models. However, these models were primarily developed based on retrospective analyses of patients from Western countries at 1 year after RYGB. The present study was to assess the performance of these models and identify the optimal model, for predicting postoperative diabetes remission in diabetic Chinese patients.
METHODS: The present study included a total of 253 RYGB patients; 214 completed a 1-year follow-up and 131 completed a 3-year follow-up. The assessments and comparisons of the predictive performance of the four models were based on both discrimination and calibration measures. Discrimination was assessed according to the area under the receiver operating characteristic curve (AUC), and calibration was evaluated by Hosmer-Lemeshow goodness-of-fit tests and predicted-to-observed ratios.
RESULTS: One hundred thirteen (52.8%) in the 1-year follow-up group and 59 (45.0%) in the 3-year follow-up group achieved complete diabetes remission. Although all models showed similar discriminatory capacity and good calibration, the DiaBetter model exhibited the best predictive performance (1-year follow-up, AUC 0.760, 95% confidence interval [CI] 0.697-0.815, predicted-to-observed ratio 1.04; 3-year follow-up, AUC 0.804, 95% CI 0.726-0.868, predicted-to-observed ratio 0.95).
CONCLUSIONS: The present results indicated that the DiaBetter model is the optimal model for predicting postoperative diabetes remission in diabetic Chinese individuals, due to its excellent predictive accuracy and ready availability for use in clinical practice.

Entities:  

Keywords:  Bariatric surgery; Diabetes remission; Obesity; Risk prediction models; Roux-en-Y gastric bypass; Type 2 diabetes mellitus

Mesh:

Year:  2020        PMID: 31898049     DOI: 10.1007/s11695-019-04371-9

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  5 in total

1.  Validation of Ad-DiaRem and ABCD Diabetes Remission Prediction Scores at 1-Year After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy in the Randomized Controlled Oseberg Trial.

Authors:  Farhat Fatima; Jøran Hjelmesæth; Jens Kristoffer Hertel; Marius Svanevik; Rune Sandbu; Milada Cvancarova Småstuen; Dag Hofsø
Journal:  Obes Surg       Date:  2022-01-04       Impact factor: 4.129

2.  Comparison of Preoperative Remission Scores and Diabetes Duration Alone as Predictors of Durable Type 2 Diabetes Remission and Risk of Diabetes Complications After Bariatric Surgery: A Post Hoc Analysis of Participants From the Swedish Obese Subjects Study.

Authors:  Kajsa Sjöholm; Lena M S Carlsson; Magdalena Taube; Carel W le Roux; Per-Arne Svensson; Markku Peltonen
Journal:  Diabetes Care       Date:  2020-09-01       Impact factor: 19.112

3.  Is Bariatric Surgery Effective for Chinese Patients with Type 2 Diabetes Mellitus and Body Mass Index < 35 kg/m2? A Systematic Review and Meta-analysis.

Authors:  Yichen Li; Yijie Gu; Yujia Jin; Zhongqi Mao
Journal:  Obes Surg       Date:  2021-07-10       Impact factor: 4.129

4.  Metabolic surgery in China: present and future.

Authors:  Yinfang Tu; Yuqian Bao; Pin Zhang
Journal:  J Mol Cell Biol       Date:  2021-07-07       Impact factor: 6.216

5.  External validation of predictive scores for diabetes remission after metabolic surgery.

Authors:  Izabela A Karpińska; Joanna Choma; Michał Wysocki; Alicja Dudek; Piotr Małczak; Magdalena Szopa; Michał Pędziwiatr; Piotr Major
Journal:  Langenbecks Arch Surg       Date:  2021-07-13       Impact factor: 2.895

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.